- Home
- CGEN vs EDF Comparison
CGEN vs EDF Comparison
Compare CGEN & EDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGEN
- EDF
- Stock Information
- Founded
- CGEN 1993
- EDF 2010
- Country
- CGEN Israel
- EDF United States
- Employees
- CGEN N/A
- EDF N/A
- Industry
- CGEN Biotechnology: Biological Products (No Diagnostic Substances)
- EDF Investment Managers
- Sector
- CGEN Health Care
- EDF Finance
- Exchange
- CGEN Nasdaq
- EDF Nasdaq
- Market Cap
- CGEN 142.4M
- EDF 148.6M
- IPO Year
- CGEN 2000
- EDF N/A
- Fundamental
- Price
- CGEN $2.25
- EDF $5.01
- Analyst Decision
- CGEN Strong Buy
- EDF
- Analyst Count
- CGEN 1
- EDF 0
- Target Price
- CGEN $4.00
- EDF N/A
- AVG Volume (30 Days)
- CGEN 898.9K
- EDF 160.6K
- Earning Date
- CGEN 03-04-2025
- EDF 01-01-0001
- Dividend Yield
- CGEN N/A
- EDF 13.14%
- EPS Growth
- CGEN N/A
- EDF N/A
- EPS
- CGEN 0.02
- EDF N/A
- Revenue
- CGEN $59,852,000.00
- EDF N/A
- Revenue This Year
- CGEN $57.27
- EDF N/A
- Revenue Next Year
- CGEN N/A
- EDF N/A
- P/E Ratio
- CGEN $125.59
- EDF N/A
- Revenue Growth
- CGEN 698.03
- EDF N/A
- 52 Week Low
- CGEN $1.35
- EDF $3.51
- 52 Week High
- CGEN $3.03
- EDF $5.50
- Technical
- Relative Strength Index (RSI)
- CGEN 81.70
- EDF 54.60
- Support Level
- CGEN $1.92
- EDF $4.96
- Resistance Level
- CGEN $2.16
- EDF $5.13
- Average True Range (ATR)
- CGEN 0.15
- EDF 0.08
- MACD
- CGEN 0.07
- EDF 0.02
- Stochastic Oscillator
- CGEN 88.90
- EDF 72.22
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902, bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.
About EDF Virtus Stone Harbor Emerging Markets Income Fund of Beneficial Interest
Virtus Stone Harbor Emerging Markets Income Fund is a closed-end management investment company. Its investment objective is to maximize total return, which consists of income from its investments and capital appreciation. The Fund invests predominantly invests in fixed income securities and other instruments economically tied to emerging market countries.